Loading company…
Swiss biopharmaceutical company developing inhaled murepavadin and balixafortide for rare diseases and oncology.
Founded in 1996 in Allschwil, Switzerland, Spexis Ltd is a biopharmaceutical company focused on rare diseases and oncology. Its products include inhaled murepavadin for Pseudomonas aeruginosa infections in cystic fibrosis and non-CF bronchiectasis, and balixafortide, a CXCR4 inhibitor studied in solid tumors and hematologic malignancies. Jeffrey Wager is CEO. In May 2018 it raised USD 2.50 mn in Venture Debt, bringing total raised to USD 6.80 mn across 8 deals. Its partnership with Fosun Pharma supports expansion into China.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in